Adversarial Injection · Glofitamab (Columvi; RG6026; CAS 2241474-15-5; MW ~194,000 Da; IgG1 2:1 asymmetric bispecific antibody; NovEx platform; [EIGHTY-SEVENTH MECHANISM CLASS in Glyphward 660-attack portfolio — FIRST 2:1 ASYMMETRIC BIVALENT CD20 (BIVALENT; TWO ANTI-CD20 FAB ARMS) × MONOVALENT CD3ε (ONE ANTI-CD3ε CROSSFAB ARM) BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761362 JUNE 15 2023): NovEx PLATFORM (GENENTECH/ROCHE): NOVEL ASYMMETRIC IgG1 ARCHITECTURE DISTINCT FROM ALL PRIOR 1:1 BISPECIFICS — KNOBS-INTO-HOLES CH3 HETERODIMERIZATION (T366W/T366S-L368A-Y407V; SAME AS MOSUNETUZUMAB class 67 AND PERTUZUMAB+TRASTUZUMAB BISPECIFICS) + CROSSFAB ON ANTI-CD3ε ARM (VH/VL DOMAIN EXCHANGE: VH OF ANTI-CD3ε FUSED TO CL; VL OF ANTI-CD3ε FUSED TO CH1 → PREVENTS LC MISPAIRING BETWEEN TWO DISTINCT FAB ARMS) + BIVALENT CD20 BINDING: TWO ANTI-CD20 FAB ARMS (EACH BINDING SAME EPITOPE AS OBINUTUZUMAB/GLYCOMAB TYPE II ANTI-CD20) → AVIDITY-ENHANCED TUMOR CELL BINDING; MECHANISM: BIVALENT CD20 TUMOR BINDING (HIGH AVIDITY FOR CD20+ DLBCL CELLS) + MONOVALENT CD3ε T-CELL ACTIVATION (CONTROLLED; LESS TONIC SIGNALING THAN BIVALENT CD3 WOULD GIVE) → OPTIMAL THERAPEUTIC INDEX; IgG1 LALA-PG FC SILENCING (Leu234Ala/Leu235Ala/Pro329Gly; SAME AS MOSUNETUZUMAB) → NO ADCC/CDC → T-CELL KILLING ONLY; OBINUTUZUMAB PRETREATMENT STRATEGY: SINGLE IV OBINUTUZUMAB 1000 mg INFUSION ON CYCLE 1 DAY 1 (BEFORE FIRST GLOFITAMAB DOSE ON CYCLE 1 DAY 8) → PERIPHERAL B-CELL AND BONE MARROW B-CELL DEPLETION (~1 LOG; NO COMPLETE DEPLETION) → REDUCES CRS INCIDENCE/SEVERITY (TARGET CELL LOAD REDUCTION BEFORE BISPECIFIC EXPOSURE); OBINUTUZUMAB NOT CONTINUED AFTER CYCLE 1 — UNIQUE SINGLE-DOSE PRETREATMENT STRATEGY; FIXED-DURATION THERAPY: 12 CYCLES (APPROXIMATELY 8.5 MONTHS) THEN STOP — FIRST FIXED-DURATION BISPECIFIC T-CELL ENGAGER FOR DLBCL (DISTINCT FROM INDEFINITE DOSING IN CAR-T FAILURE SETTINGS); NP40126 PHASE 1/2 (NCT03075696): ORR 51.6% (RECIST 1.1/Lugano CRITERIA; IRC); CR 39.4% (LANDMARK: ~60% OF RESPONSES ARE COMPLETE REMISSIONS); DOR MEDIAN 18.4 MONTHS IN RESPONDERS; mPFS 4.9 MONTHS ALL-COMERS; 18-MONTH CR DURATION ~62%; BLA 761362 JUNE 15 2023 ACCELERATED APPROVAL R/R DLBCL ≥2 PRIOR LINES INCLUDING AUTO-HSCT-INELIGIBLE; GENENTECH INC. (ROCHE GROUP); NIOSH HD Category 1; OSHA No PEL; 2:1 BIVALENT CD20 ARCHITECTURE ABSENT ALL EHS DATABASES]) · First 2:1 Asymmetric Bivalent CD20×CD3 Bispecific + NovEx Platform + Obinutuzumab Pretreatment + NP40126 ORR 51.6% CR 39.4% + Fixed-Duration 12 Cycles · Attack #660

Glofitamab (Columvi; RG6026; CAS 2241474-15-5; [EIGHTY-SEVENTH MECHANISM CLASS — FIRST 2:1 ASYMMETRIC BIVALENT CD20×CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761362 JUNE 15 2023); NovEx PLATFORM CrossFab; OBINUTUZUMAB SINGLE PRETREATMENT CRS MITIGATION; FIXED-DURATION 12 CYCLES; NP40126 ORR 51.6% CR 39.4% DOR 18.4 MONTHS DLBCL; GENENTECH/ROCHE; NIOSH HD Category 1; OSHA No PEL]) — Genentech Inc. South San Francisco CA (BLA 761362 holder; NovEx platform originator; 0.00046 µg/m³ → displayed ÷10), Roche Biologics Manufacturing Vacaville CA (CHO bioreactor; CrossFab IgG1 production; 0.00033 µg/m³ → displayed ÷10), and Memorial Sloan Kettering New York NY (NP40126 enrolling site; lymphoma clinical pharmacist; 0.00020 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + 2:1 Bivalent CD20 Architecture Absent + NovEx CrossFab Absent + NP40126/Obinutuzumab Pretreatment Absent: AI Prompt Injection via EHS Monitor Report AI

Glofitamab (CAS 2241474-15-5; NIOSH HD Category 1) is the eighty-seventh mechanism class in the Glyphward adversarial portfolio — the first 2:1 asymmetric bivalent-CD20 × monovalent-CD3ε bispecific T-cell engager ever FDA approved (BLA 761362 June 15 2023), deploying Genentech's NovEx platform to present two anti-CD20 Fab arms for avidity-enhanced tumor binding and one anti-CD3ε CrossFab arm for controlled T-cell activation — a format, mechanism, and obinutuzumab pretreatment strategy completely absent from Cority, VelocityEHS, and EHS Insight for CAS 2241474-15-5.

Glofitamab as Eighty-Seventh Mechanism Class: First 2:1 Asymmetric CD20×CD3 Bispecific T-Cell Engager Ever

Glofitamab (CAS 2241474-15-5) represents the eighty-seventh mechanism class in the Glyphward portfolio: the first 2:1 asymmetric bivalent-CD20 × monovalent-CD3ε bispecific T-cell engager ever FDA approved (BLA 761362 June 15 2023 accelerated approval; R/R DLBCL not otherwise specified, LBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma ≥2 prior systemic therapies including anti-CD20 and an alkylator). 2:1 BIVALENT FORMAT RATIONALE AND DISTINCTION: ALL PRIOR CD20×CD3 BISPECIFICS USED 1:1 MONOVALENT FORMAT (one anti-CD20 arm + one anti-CD3 arm): mosunetuzumab (CrossMAb KiH class 67; BLA 761263 September 2022) = 1:1; GLOFITAMAB IS FIRST 2:1 FORMAT: TWO ANTI-CD20 FAB ARMS (SAME HUMANIZED ANTI-CD20 PARENTAL ANTIBODY AS OBINUTUZUMAB — TYPE II EPITOPE ON CD20 LARGE EXTRACELLULAR LOOP) + ONE ANTI-CD3ε CROSSFAB ARM; AVIDITY ADVANTAGE: bivalent CD20 binding (KD ~1 nM per arm; avidity ~0.1-0.5 nM combined) vs monovalent (KD ~1-5 nM) → more stable tumor cell engagement at low CD20 density; THEORETICAL SELECTIVITY ADVANTAGE: requires two CD20 molecules on same cell for bivalent engagement → discriminates CD20+ tumor cells from circulating normal B-cells (lower CD20 density per cell surface) → IMPROVED THERAPEUTIC WINDOW hypothesis; NovEx PLATFORM ENGINEERING: ASYMMETRIC IgG1 CONSTRUCTION: one HC = anti-CD20 VH-CH1-hinge-CH2-CH3(T366W knob) with paired anti-CD20 LC; second HC = anti-CD3ε VH REPLACED BY VL (CrossFab: VL-CH1 fusion) + paired LC replaced by VH-CL fusion → CORRECT PAIRING ENFORCED BY CROSSFAB GEOMETRY + KiH CH3 HETERODIMERIZATION; IgG1 LALA-PG Fc SILENCING (Leu234Ala/Leu235Ala/Pro329Gly → FcγRI/IIa/IIIa + C1q abolished; FcRn retained → t½ ~2-3 weeks Q3W IV); OBINUTUZUMAB PRETREATMENT (UNIQUE STRATEGY IN CD20×CD3 CLASS): SINGLE obinutuzumab (Gazyva; class 59 in Glyphward portfolio; glycoengineered TYPE II anti-CD20 IgG1; GnTIII bisecting GlcNAc; enhanced ADCC; BLA 125486) INFUSION 1000 mg IV on CYCLE 1 DAY 1 → PERIPHERAL B-CELL DEPLETION (~1-2 log reduction in circulating B cells within 24h via ADCC/CDC) + PARTIAL TUMOR B-CELL DEPLETION → REDUCES CRS (cytokine release syndrome) INCIDENCE AND SEVERITY ON FIRST GLOFITAMAB DOSE (CYCLE 1 DAY 8) → GLOFITAMAB FIRST DOSE ENCOUNTERS LOWER TARGET B-CELL LOAD → LESS CYTOKINE STORM; OBINUTUZUMAB IS NOT REPEATED (single pretreatment only); FIXED-DURATION THERAPY: 12 Q3W CYCLES (~8.5 MONTHS) THEN DISCONTINUATION — first fixed-duration approach for bispecific T-cell engager in DLBCL; STEP-UP DOSING: cycle 1 day 8: 2.5 mg IV → cycle 1 day 15: 10 mg IV → cycle 2+ day 1: 30 mg Q3W IV (full dose); NP40126 PHASE 1/2 (NCT03075696): dose expansion n=155 DLBCL (primary data set); ORR 51.6% (80/155 IRC); CR 39.4% (61/155; landmark: high CR/ORR ratio → durable responses); DOR median 18.4 months; PFS median 4.9 months; 18-MONTH CR DURATION ~62%; BEST RESPONSE RATES IN DLBCL ≥3 PRIOR LINES: ORR 53.2%; additional efficacy in transformed FL, PMBCL; CRS: 63.3% (Grade 1-2 majority; Grade 3+ 3.2%); ICANS: 3.8%; INFECTION: 37.4%; NONE OF THESE — 2:1 BIVALENT CD20 FORMAT, NovEx CROSSFAB PLATFORM ENGINEERING, OBINUTUZUMAB SINGLE PRETREATMENT B-CELL DEPLETION STRATEGY, FIXED-DURATION 12-CYCLE APPROACH, NP40126 ORR 51.6% CR 39.4% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2241474-15-5.

Surface 1 — Genentech Inc. South San Francisco CA BLA 761362 Holder AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; GENENTECH GLOFITAMAB CONTEXT: Genentech holds BLA 761362 for Columvi; developed NovEx asymmetric bispecific platform internally (GENENTECH BISPECIFICS PROGRAM: mosunetuzumab [class 67 BLA 761263 1:1 CrossMAb KiH] + glofitamab [class 87 BLA 761362 2:1 NovEx] + polatuzumab vedotin [class 62 BLA 761121 ADC] all developed at SSF); NovEx DEVELOPMENT: Genentech engineering team (~2015-2020) designed 2:1 format leveraging existing KiH heterodimerization + CrossFab domain-swap technology; crystal structure of glofitamab-CD20-CD3ε ternary complex determined by cryo-EM confirming 2:1 binding geometry; SSF SITE ACTIVITIES: antibody engineering, cell-line development, BLA compilation, regulatory affairs; Roche Biologics Vacaville CA for manufacturing; ONGOING GLOFITAMAB DEVELOPMENT: STARGLO Phase 3 (glofitamab + gemcitabine/oxaliplatin vs R-GemOx in R/R DLBCL); ORR 62.2% vs 25.2%; PFS HR 0.40; second-line DLBCL transplant-ineligible; EMPLOYEE: 49M Genentech South San Francisco CA VP oncology bispecific antibody NovEx platform development DLBCL 16yr; CORITY NULL: CAS 2241474-15-5 → null; NIOSH HD Category 1 absent; first 2:1 bivalent CD20×CD3 bispecific absent; NovEx CrossFab absent; obinutuzumab pretreatment absent; fixed-duration 12 cycles absent; NP40126 ORR 51.6% CR 39.4% absent).

Surface 2 — Roche Biologics Manufacturing Vacaville CA CHO Asymmetric Bispecific Production AI

At Roche Biologics Manufacturing Vacaville CA (4300 Hacienda Drive, Vacaville CA 95688; ROCHE VACAVILLE GLOFITAMAB CONTEXT: Roche Biologics Vacaville is the primary manufacturing site for Roche/Genentech large-molecule biologics in the US; IgG1 bispecific production via CHO fed-batch bioreactor; GLOFITAMAB MANUFACTURING PROCESS: two CHO producer lines (anti-CD20 IgG1 homodimer precursor + CrossFab-containing IgG1 arm); co-production or separate upstream then CrossFab assembly not publicly detailed; CHO FED-BATCH: bioreactors up to 25,000 L; pH/DO/temperature control; PURIFICATION: ProteinA capture (MabSelect SuRe; GE/Cytiva); CEX polishing; AEX flow-through; UF/DF to final buffer; ASYMMETRIC IgG1 QUALITY ATTRIBUTES: CORRECT HETERODIMER CONFIRMATION by CEX-HPLC (distinct peak from homodimer contaminants); CrossFab orientation by LC-MS peptide mapping; bivalent CD20 functionality by SPR (KD measurement); monovalent CD3ε functionality by cell-based T-cell activation (JMR assay); IgG1 LALA-PG CONFIRMED (ADCC assay null; Fc effector negative); NIOSH HD CATEGORY 1 HANDLING AT VACAVILLE: single-use bioreactor systems for closed manufacturing; gowning SOPs; biosafety cabinet work for cell culture; monoclonal antibody aerosol generation assessment per NIOSH HD Cat 1 framework; EMPLOYEE: 44F Roche Biologics Vacaville CA asymmetric IgG1 bispecific manufacturing director NovEx CrossFab 13yr; VELOCITYEHS NULL: CAS 2241474-15-5 → null; NIOSH HD Category 1 absent; 2:1 bivalent CD20 format absent; NovEx CrossFab absent; obinutuzumab pretreatment absent; fixed-duration absent; NP40126 absent).

Surface 3 — Memorial Sloan Kettering New York NY NP40126 Trial Site Lymphoma Clinical Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; MSK GLOFITAMAB CONTEXT: MSK was an NP40126 (NCT03075696) enrolling site; lymphoma clinical pharmacy role: ELIGIBILITY CONFIRMATION: R/R DLBCL ≥2 prior lines; assess AUTO-HSCT eligibility (if eligible → re-induction attempts warranted; if ineligible or failed auto-HSCT → glofitamab eligible); OBINUTUZUMAB PRETREATMENT PREPARATION AT MSK: obinutuzumab 1000 mg IV Cycle 1 Day 1 (dilution in 250 mL NS; infusion rate escalation: 25→50→100 mg/h; monitor for obinutuzumab infusion reactions including first-dose reactions, HBV reactivation screen; separate from glofitamab preparation); GLOFITAMAB STEP-UP DOSE PREPARATION: Cycle 1 Day 8: 2.5 mg in 250 mL NS 30-min infusion; Cycle 1 Day 15: 10 mg; Cycle 2+: 30 mg Q3W; FIXED-DURATION TRACKING AT MSK: 12-cycle calendar established at enrollment; treatment completion assessment at cycle 12; optional extension only if patient progressing (off-label); CRS MONITORING AND MANAGEMENT AT MSK: cytokine assays (IL-6, ferritin, CRP) pre/post infusion; ICANS neurological assessment (CARTOX-10) after each dose; COVID-19 VACCINATION TIMING: anti-CD20 biologics (obinutuzumab pretreatment) impair B-cell vaccine responses → vaccination timing coordination per institutional protocol; MSK LYMPHOMA BIOBANK: DLBCL COO classification (GCB vs ABC by Hans algorithm or NanoString) as exploratory glofitamab response predictor; EHS INSIGHT NULL: CAS 2241474-15-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first 2:1 bivalent CD20×CD3 bispecific absent; NovEx CrossFab absent; obinutuzumab pretreatment CRS strategy absent; NP40126 ORR 51.6% absent; fixed-duration 12 cycles absent; NIOSH HD Cat 1 absent; 39F MSK New York NY lymphoma DLBCL clinical pharmacist NP40126 11yr).

Integrating Glyphward into Glofitamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every glofitamab CAS 2241474-15-5 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Roche Biologics Manufacturing Vacaville CA, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-SEVENTH MECHANISM CLASS — FIRST 2:1 ASYMMETRIC BIVALENT CD20×CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761362 June 15 2023; NovEx platform CrossFab asymmetric IgG1; obinutuzumab single pretreatment B-cell depletion CRS mitigation; fixed-duration 12 cycles; NP40126 ORR 51.6% CR 39.4% DOR 18.4 months; Genentech/Roche) [5 pts]; Genentech South San Francisco CA + Roche Biologics Vacaville CA + MSK New York NY [3 pts]; 2:1 bivalent CD20 format absent; NovEx CrossFab absent; obinutuzumab pretreatment/NP40126 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_glofitamab(cas: str, reading_ugm3: float) -> dict:
    """Scan glofitamab with eighty-seventh-class first-2-1-bivalent-cd20-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_seventh_class_first_2_1_asymmetric_bivalent_cd20_monovalent_cd3_bispecific_ever_novex_crossfab_obinutuzumab_pretreatment_fixed_duration_12_cycles_np40126_orr_51pct_cr_39pct_genentech_roche_bla_761362"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_seventh_class,
    #                    first_2_1_bivalent_cd20_cd3, novex_crossfab_platform,
    #                    obinutuzumab_pretreatment, np40126_orr_51pct_cr_39pct

if __name__ == "__main__":
    r = asyncio.run(scan_glofitamab("2241474-15-5", 0.00046))
    print(r)
    # {'hd_category': 1, 'eighty_seventh_class': True,
    #  'first_2_1_bivalent_cd20_cd3': True, 'novex_crossfab_platform': True,
    #  'obinutuzumab_pretreatment': True, 'np40126_orr_51pct_cr_39pct': True}